TY - JOUR
T1 - Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival
AU - Kitagawa, Yuichiro
AU - Kawamura, Itta
AU - Suzuki, Keiko
AU - Okada, Hideshi
AU - Ishihara, Takuma
AU - Tomita, Hiroyuki
AU - Suzuki, Kodai
AU - Takada, Chihiro
AU - Sampei, So
AU - Kano, Soichiro
AU - Kondo, Kohei
AU - Asano, Hirotaka
AU - Wakayama, Yugo
AU - Kamidani, Ryo
AU - Kawasaki, Yuki
AU - Fukuda, Hirotsugu
AU - Nishio, Ayane
AU - Miyake, Takahito
AU - Fukuta, Tetsuya
AU - Yasuda, Ryu
AU - Oiwa, Hideaki
AU - Kakino, Yoshinori
AU - Miyazaki, Nagisa
AU - Watanabe, Takatomo
AU - Yoshida, Takahiro
AU - Doi, Tomoaki
AU - Suzuki, Akio
AU - Yoshida, Shozo
AU - Matsuo, Hitoshi
AU - Ogura, Shinji
N1 - Publisher Copyright:
© 2021 Kitagawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/12
Y1 - 2021/12
N2 - Syndecan-1 is found in the endothelial glycocalyx and is released into the bloodstream during stressed conditions, including severe diseases such as acute kidney injury, chronic kidney disease, and cardiovascular disease. This study investigated the prognostic value of serum syndecan-1 concentration in patients with heart failure upon admission. Serum syndecan- 1 concentration was analyzed in 152 patients who were hospitalized for worsening heart failure from September 2017 to June 2018. The primary outcome of the study was readmission-free survival, defined as the time from the first admission to readmission for worsened heart failure or death from any cause, which was assessed at 30 months after discharge from the hospital. The secondary outcome of the study was survival time. Blood samples and echocardiogram data were analyzed. Univariate and multivariable time-dependent Cox regression analyses adjusted for age, creatinine levels, and use of antibiotics were conducted. The serum syndecan-1 concentration was significantly associated with readmission- free survival. Subsequently, the syndecan-1 concentration may have gradually decreased with treatment. The administration of human atrial natriuretic peptide and antibiotics may have modified the relationship between readmission-free survival and serum syndecan- 1 concentration (p = 0.01 and 0.008, respectively). Serum syndecan-1 concentrations, which may indicate injury to the endothelial glycocalyx, predict readmissionfree survival in patients with heart failure.
AB - Syndecan-1 is found in the endothelial glycocalyx and is released into the bloodstream during stressed conditions, including severe diseases such as acute kidney injury, chronic kidney disease, and cardiovascular disease. This study investigated the prognostic value of serum syndecan-1 concentration in patients with heart failure upon admission. Serum syndecan- 1 concentration was analyzed in 152 patients who were hospitalized for worsening heart failure from September 2017 to June 2018. The primary outcome of the study was readmission-free survival, defined as the time from the first admission to readmission for worsened heart failure or death from any cause, which was assessed at 30 months after discharge from the hospital. The secondary outcome of the study was survival time. Blood samples and echocardiogram data were analyzed. Univariate and multivariable time-dependent Cox regression analyses adjusted for age, creatinine levels, and use of antibiotics were conducted. The serum syndecan-1 concentration was significantly associated with readmission- free survival. Subsequently, the syndecan-1 concentration may have gradually decreased with treatment. The administration of human atrial natriuretic peptide and antibiotics may have modified the relationship between readmission-free survival and serum syndecan- 1 concentration (p = 0.01 and 0.008, respectively). Serum syndecan-1 concentrations, which may indicate injury to the endothelial glycocalyx, predict readmissionfree survival in patients with heart failure.
UR - http://www.scopus.com/inward/record.url?scp=85120894432&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0260350
DO - 10.1371/journal.pone.0260350
M3 - 学術論文
C2 - 34879094
AN - SCOPUS:85120894432
SN - 1932-6203
VL - 16
JO - PLoS ONE
JF - PLoS ONE
IS - 12 December
M1 - e0260350
ER -
